Spotlight
Specialty
Partners
CME/CE
Translating Evidence to Practice to Improve Outcomes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma : Episode 10
Future of R/R DLBCL
A panel of experts discuss the future of R/R DLBCL treatment and review some recent data from the 2022 ASH meeting.
EP: 1.Front-Line Treatment Options for Patients with DLBCL
EP: 2.An Overview of R/R DLBCL
EP: 3.Treatment Options for Patients with R/R DLBCL
EP: 4.L-MIND: Review of Long-Term Analyses Data
EP: 5.Role of CAR T-cell Therapy in Patients with R/R DLBCL
EP: 6.Eligibility Criteria for CAR T-Cell Therapy in R/R DLBCL
EP: 7.ZUMA-7: Clinical Implications
EP: 8.Sequencing Therapies in Patients with R/R DLBCL
EP: 9.Potential Role of CAR T-cell Therapy in the Front-line Setting for Patients with R/R DLBCL
Now Viewing
EP: 10.Future of R/R DLBCL
Related Videos
Related Content
